Please provide your email address to receive an email when new articles are posted on . “Despite this substantial clinical overlap and the recognition of AF as a potential therapeutic target in HF ...

Dronedarone is a novel antiarrhythmic drug with electrophysiological properties that are similar to those of amiodarone, but it does not contain iodine and thus does not cause iodine-related adverse ...

Dronedarone is associated with a reduction in recurrent AF and may have other potential benefits. According to Richard L. Page, MD, president of the Heart Rhythm Society and a professor of medicine ...

Hammill's colleague, HRS past-president Dr Michael Cain, agreed. "We desperately would benefit from an antiarrhythmic drug that worked as well as amiodarone but had an improved safety profile." The ...

Two phase 3 trials of dronedarone, a novel class III antiarrhythmic agent currently in development worldwide, have demonstrated that the drug is safe and effective for the maintenance of normal sinus ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended new restriction on dronedarone (Multaq), Sanofi's embattled and controversial antiarrhythmic drug.

Discover comprehensive details about Dronedarone, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of dronedarone, having considered evidence on the nature of atrial fibrillation and the value placed on the ...

Amiodarone effectively maintains sinus rhythm in patients with atrial fibrillation, and although dronedarone is less effective it has a better safety profile. The choice of antiarrhythmic drug (or ...

The Appraisal Committee considered evidence submitted by the manufacturer of dronedarone and a review of this submission by the Evidence Review Group (ERG). The main clinical evidence on dronedarone ...